ALNY Alnylam Pharmaceuticals Inc.

78.18
+1.97  (+3%)
Previous Close 76.21
Open 76.32
Price To Book 6.38
Market Cap 8300918407
Shares 106,177,007
Volume 609,498
Short Ratio
Av. Daily Volume 902,897

NewsSee all news

  1. Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2018
  2. Is Moderna a Buy?
  3. Alnylam Pharmaceuticals Is Launched and Ready for More
  4. Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group — What Drives Growth in Today's Competitive Landscape
  5. Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT

SEC filingsSee all SEC filings

  1. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19608514
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19603789
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594496
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588054

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Fitusiran
Hemophilia A and B
Phase 3 positive interim analysis reported September 27, 2018. Data due March 2019. Rolling NDA has been initiated.
Givosiran
Acute hepatic porphyrias
Phase 3 data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Phase 1/2 data due 2019.
ALN-HBV02 (VIR-2218))
Chronic hepatitis B virus (HBV)
Phase 3 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-A
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial to be initiated.
ALN-CC5 (cemdisiran)
IgA nephropathy
Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Hemophilia
Phase 3 trial enrolling - noted December 6, 2018.
ALN-TTRsc02 - HELIOS-A
ATTR amyloidosis
Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 data due 2019.
ALN-AAT02
alpha-1 anti-trypsin deficiency-associated liver disease

Latest News

  1. Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2018
  2. Is Moderna a Buy?
  3. Alnylam Pharmaceuticals Is Launched and Ready for More
  4. Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group — What Drives Growth in Today's Competitive Landscape
  5. Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT
  6. The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs
  7. See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
  8. Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates
  9. Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call Transcript
  10. Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
  11. Alnylam: 4Q Earnings Snapshot
  12. Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
  13. Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine
  14. Alnylam to Webcast Presentations at Upcoming February Investor Conferences
  15. Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
  16. Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics
  17. The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
  18. 5 Best Biotech Bets Likely to Outperform Estimates in Q4
  19. Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs

SEC Filings

  1. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 19608514
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19603789
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19594496
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588054
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583899
  7. 8-K - Current report 19575350
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19562108
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19555623
  10. 8-K - Current report 19527687